NCT01028755已完成1 期
An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 12
- 主要终点
- Safety, tolerability, maximum tolerated dose
研究概览
简要总结
This is the first time this drug will be tested in humans in order to determine the safety of the drug, the ability to tolerate the drug, to measure how the drug is used in the body and as a result of these tests to determine a maximum dose to be given. Specifically, the following aspects will be investigated:
- side effects of BAY79-4620 given as infusion every three weeks
- evaluation of highest and safest dose of BAY79-4620
- distribution and concentration of BAY79-4620 in the blood at specific times after administration
- effect of BAY79-4620 on tumor growth
- assessment of "biomarkers" (eg, analysis of specific proteins in blood samples, or analysis of tumor tissue sampled at the time of cancer diagnosis) for changes during the treatment or prediction of safety or benefits of the treatment with BAY79-4620.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than/equal to 18 years old.
- •ECOG Performance Status of 0 - 2
- •Life expectancy of at least 12 weeks
- •Patients with advanced, histologically or cytological confirmed solid tumors, refractory to any standard therapy or have no standard therapy available
- •Radiographically or clinically evaluable tumor
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to start of first dose:
- •Hemoglobin > 10.0 g/dL
- •Absolute neutrophil count (ANC) > or = 1500/mm3
- •Platelet count > or = 100,000 /mm3
- •Total bilirubin < or = 1.5 times the upper limit of normal
- •ALT and AST < or = 2.5 x upper limit of normal (< or = 5 x upper limit of normal for patients with liver involvement)
- •INR less than or = 1.5 and a PTT within normal limits (patients who do not undergo an anticoagulative treatment, but have an abnormal high PTT while INR is normal, indicating towards an artificial PTT elevation caused by heparinized, are eligible.
- •Serum creatinine < 1.5 times the upper limit of normal
排除标准
- •History of impaired cardiac function or clinically significant cardiac disease (i.e. congestive heart failure (CHF) NYHA Class III or IV); myocardial infarction, unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy < 6 months prior to study entry (beta blockers or digoxin are permitted) and LVEF <40% (as measured at screening by MUGA or echocardiogram).
- •Patients with amylase or lipase greater than upper limit of normal range per local laboratory
- •History of pancreatitis
- •Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 90 mmHg, despite optimal medical management
- •Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has no evidence of tumor growth on an imaging study within 2 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry.
- •Patients with severe renal impairment or on dialysis
- •Known human immunodeficiency virus (HIV) infection or patients with an active hepatitis B or C infection necessitating treatment. Patients with chronic hepatitis B or C are eligible
- •Active clinically serious infections > CTCAE Grade 2
- •Serious, non-healing wound, ulcer, or bone fracture
- •Known or suspected allergy or intolerance to any agent given in the course of this trial
- •Previous cancer that is distinct in primary site or histology from actual disease EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors [Ta and Tis] or any cancer curatively treated > 3 years prior to study entry
研究组 & 干预措施
Arm 1
Experimental
干预措施: BAY79-4620 (Drug)
结局指标
主要结局
Safety, tolerability, maximum tolerated dose
时间窗: 2 years
Pharmacokinetics profile of BAY79-4620 and its key metabolites
时间窗: 2 years
次要结局
- Immunogenicity(2 years)
- Biomarker evaluation(2 years)
- Tumor response(2 years)
研究者
相似试验
终止
1 期
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693CancerNCT00493818GlaxoSmithKline70
Unknown
1 期
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid TumorsAdvanced/Metastatic Solid TumorsNCT05394168Shanghai Henlius Biotech12
终止
1 期
Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabGRabiesNCT04162600University of Oxford18
招募中
1 期
Study of DNP002 in Patients With Solid TumorsAdvanced Solid TumorNCT06466265Kumho HT Inc.36
尚未招募
1 期
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or LymphomaSolid Tumor, Adult LymphomaNCT05788107Shanghai Henlius Biotech30